Lead Product(s): TXA709
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Boston University
Deal Size: $14.6 million Upfront Cash: $3.2 million
Deal Type: Funding January 14, 2020
Funding aims to develop Efflux Pump Inhibitors (EPIs), representing a new drug class designed to address a major mechanism of multi-drug-resistant (MDR) Pseudomonas aeruginosa bacteria.